AngioDynamics, Inc. (ANGO) Financial Statements
AngioDynamics, Inc. (ANGO) reported trailing twelve-month revenue of $325.4M (up 8.2% year on year) and net income of -$32.9M as of 2026-08-31, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $1.4M.
Source: SEC EDGAR filings · figures as of 2026-08-31 · read by EquiReason
ANGOAngioDynamics, Inc.Follow ANGO — free
—
Price chart with a free account
- Market cap
- 520.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Jan, in 72 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Aug 26.
| Line | FY2011 May 11 | FY2012 May 12 | FY2013 May 13 | FY2014 May 14 | FY2015 May 15 | FY2016 May 16 | FY2017 May 17 | FY2018 May 18 | FY2019 May 19 | FY2020 May 20 | FY2021 May 21 | FY2022 May 22 | FY2023 May 23 | FY2024 May 24 | FY2025 May 25 | FY2026 May 26 | TTM Aug 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 215.6 | 221.9 | 341.9 | 354.4 | 356.5 | 353.9 | 349.6 | 261.7 | 270.6 | 264.2 | 291.0 | 316.2 | 338.8 | 303.9 | 292.5 | 320.2 | 325.4 | |
| Gross profit | 125.6 | 125.3 | 168.5 | 180.2 | 175.8 | 174.3 | 144.0 | 143.9 | 156.0 | 150.3 | 156.8 | 165.7 | 174.2 | 154.7 | 157.7 | 174.9 | 181.1 | |
| Research & development | — | 20.5 | 26.1 | 28.1 | 26.6 | 25.1 | 24.1 | 24.3 | 28.3 | 29.7 | 36.4 | 30.7 | 29.9 | 31.5 | 26.2 | 29.4 | 31.0 | |
| Operating income | 11.9 | -5.2 | 5.2 | 10.5 | -3.4 | 1.0 | -11.2 | -14.2 | -9.4 | -167.1 | -35.3 | -28.5 | -51.2 | -192.4 | -40.0 | -39.9 | -36.6 | |
| Pre-tax income | 10.6 | -5.7 | -1.3 | 5.2 | -8.1 | -3.3 | -14.3 | -17.3 | -14.7 | -168.1 | -36.1 | -29.9 | -54.4 | -191.6 | -34.0 | -36.3 | -32.8 | |
| Income tax | 2.6 | -0.3 | -0.3 | -9.2 | -4.7 | 40.3 | -7.2 | -11.0 | -3.6 | -1.3 | -4.5 | -3.4 | -2.0 | -7.3 | -0.0 | 0.4 | 0.2 | |
| Net income | 8.1 | -5.3 | -1.1 | 2.3 | -3.4 | -43.6 | 5.0 | 16.3 | 61.3 | -166.8 | -31.5 | -26.5 | -52.4 | -184.4 | -34.0 | -36.7 | -32.9 | |
| Diluted EPS ($) | — | -0.20 | -0.03 | 0.07 | -0.09 | -1.21 | 0.14 | 0.44 | 1.64 | -4.39 | -0.82 | -0.68 | -1.33 | -4.59 | -0.83 | -0.88 | -0.78 | |
| Diluted shares (mn) | — | 25.4 | 34.8 | 35.4 | 35.7 | 36.2 | 36.6 | 37.1 | 37.5 | 38.0 | 38.3 | 39.0 | 39.5 | 40.2 | 40.9 | 41.5 | — |
USD millions · SEC XBRL
AngioDynamics, Inc. — questions
- What is AngioDynamics, Inc.'s revenue?
- $325.4M over the twelve months to 2026-08-31, up 8.2% year on year, from its 10-Q and 10-K filings.
- What is AngioDynamics, Inc.'s net income?
- -$32.9M over the twelve months to 2026-08-31.
- What is AngioDynamics, Inc.'s free cash flow?
- $1.4M over the twelve months to 2026-08-31.
- What are AngioDynamics, Inc.'s diluted earnings per share?
- $-0.78 over the twelve months to 2026-08-31.
Every figure on this page comes from AngioDynamics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.